Salute e Benessere

Epigenica AB Launches the Groundbreaking EpiFinder™ GenomePro - Unlocking the…

EpiFinder™ GenomePro, the next-gen version of the EpiFinder™ Genome, features optimized reagents and shorter protocols for analyzing 24 samples in a single run. With EpiFinder™ GenomePro, researchers obtain robust quantitative data for 192 genome-wide Chromatin Immunoprecipitation Sequencing (ChIP-Seq) profiles for multiple hPTMs and DNA methylation from minimal sample volumes. The reduced cost per sample is a key advantage, making large-scale studies more accessible than ever...
PR Newswire
30/09/2025

New number of shares and votes in Sobi

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Sobi is a global biopharma company unlocking the potential of breakthrough innovations,...
PR Newswire
30/09/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 30 September 2025 at 9.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 26...
Nasdaq GlobeNewswire
30/09/2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at…

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025Schlieren (Zürich), Switzerland – September 30, 2025– Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative biologic technologies, today announced the full commercial launch of the MagnetOs™ MIS Delivery System. Purpose-built for Minimally Invasive Surgical (MIS) procedures, the system is designed to meet every surgeon’s need in bone graft delivery. It will be showcased at the Kuros...
Nasdaq GlobeNewswire
30/09/2025

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya…

Long-lasting antibody persistence was comparable in older (65+) and younger adultsLong-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunyaSaint-Herblain (France), September 30, 2025– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data four years after vaccination with a single dose of its chikungunya vaccine IXCHIQ ®...
Nasdaq GlobeNewswire
30/09/2025

Data show Roche’s sixth-generation Troponin T test offers a new level of…

Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies.The test helps clinicians quickly identify heart attack and rule out non-cardiac causes, ensuring patients receive the care they need at the earliest opportunity.The global TSIX clinical study involved more than 13,000 participants, validating performance across a diverse population that reflects real-world healthcare settings. 1,2 Basel, 30...
Nasdaq GlobeNewswire
30/09/2025

Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results…

Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully throughIND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming...
Nasdaq GlobeNewswire
30/09/2025

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900…

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41) disease control rate (“DCR”) and 37% (15/41) objective response rate (“ORR”) in evaluable anti-PD-1 naïve patients per RECIST 1.174% (37/50) DCR and 32% (16/50) ORR in evaluable anti-PD-1 resistant patients per RECIST 1.115.5 months median Overall Survival (“mOS”) in evaluable anti-PD-1 naïve patients11.4 months mOS in...
Nasdaq GlobeNewswire
30/09/2025

Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first…

The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly...
PR Newswire
29/09/2025

DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology…

Key Takeaways from the DNA Synthesis Inhibitors Market Report Key Takeaways from the DNA Synthesis Inhibitors Market Report Discover which indication is expected to grab the major DNA synthesis inhibitors market share @DNA Synthesis Inhibitors Market Report Key Factors Driving the DNA Synthesis Inhibitors Market Rising clinical demand — oncology & genetic disease DNA-synthesis inhibitors remain core components of many chemotherapy regimens and are being actively...
PR Newswire
29/09/2025

uniQure Announces Closing of Upsized Public Offering and Full Exercise by…

uniQure intends to use the net proceeds from this offering to fund its commercialization readiness activities, the potential commercial launch of AMT-130 and related commercialization activities, the development of its other clinical product candidates, business development initiatives and research projects, and for general corporate purposes.Leerink Partners, Stifel, Guggenheim Securities and Van Lanschot Kempen acted as bookrunning managers for the offering. H.C. Wainwright & Co...
Nasdaq GlobeNewswire
29/09/2025

Surgical Staplers Market To Grow US$ 10,587.21 Million By 2033, Registering A…

Technology is currently evolving with the development of smart staplers that incorporate feedback and sensors that provide the surgeon with in-situ data on the properties of the tissue being stapled, which reduces complications such as leakage. Cross-pollination between stapling technologies and robotic-assisted surgical systems is a growing trend that will enhance surgeons' abilities to perform conventional surgery and work effectively with stapling instrumentation, offering greater…
PR Newswire
29/09/2025

Vantage Market Research: Global Companion Diagnostics Market Size & Share to…

Market Highlights Market Highlights Key Regional Markets Leading the Way Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making. Access the Full Study Instantly | Download Sample Pages of the Report Now@ https://www.vantagemarketresearch.com/companion-diagnostics-market-2021/request-sample Free Sample Includes: Technological & Industry Momentum Why...
PR Newswire
29/09/2025

FAMAR Group: Dr. Riku Rautsola Appointed New CEO

At the same time, FAMAR Group is pleased to announce the appointment of Dr. Riku Rautsola as CEO, effective September 29, 2025. Riku has served as a non-executive member of FAMAR's Board of Directors and an advisor to MidEuropa during the acquisition of FAMAR last year. Riku is a globally experienced leader in the pharmaceutical, biotech and CDMO industries, having held CEO and senior executive positions at several leading companies, creating sustained profitable growth At the same time…
PR Newswire
29/09/2025

IHH Healthcare Expands Collaboration with Leo Cancer Care to Advance Upright…

Proton therapy has long been recognised for its precision in targeting tumours, but adoption has been limited by the size, cost, and infrastructure demands of conventional systems. By rotating the patient rather than the beam, Leo Cancer Care's upright approach dramatically reduces system size and cost, creating a future where proton therapy is within reach for more patients. Proton therapy has long been recognised for its precision in targeting tumours, but adoption has been limited by the...
PR Newswire
29/09/2025

Fagron increases share capital through exercise subscription rights

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 29 September 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 355,000 new shares have been issued on 29 September 2025. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 506,745,841.93. The total number of shares with voting rights after the...
Nasdaq GlobeNewswire
29/09/2025

Theranexus Becomes THX Pharma: A Strategic Evolution Toward the…

With TX01 and Batten-1, THX Pharma is entering a new strategic phase focused on regulatory approval, early access, and international commercialization of its medicines. Lyon, France – September 29, 2025, 6.30 pm CEST – THX Pharma (formerly Theranexus), a pharmaceutical company specializing in rare neurological diseases, today unveils its new…
Actusnews Wire
29/09/2025

Czech Innovation Against Alzheimer's: H2 Global Group Enters Key Growth Phase

"Hydrogen is the smallest molecule in the universe, yet it can protect our most valuable assets – memory and independence," explains Prof. Ohta. "Hydrogen is the smallest molecule in the universe, yet it can protect our most valuable assets – memory and independence,"explains Prof. Ohta. Group founder David Maršálek, who has been developing hydrogen technologies since 2011, adds:"Our mission is to launch the world's first hydrogen-based medical device for Alzheimer's…
PR Newswire
29/09/2025

Interventional Cardiology Devices Market to Reach US$39,234.52 million by 2033…

The opening of more cardiac centers and outpatient cath labs, particularly in developing countries, will also drive market growth. There is a significant opportunity in developing devices that can treat complex heart conditions and in expanding into regions where advanced treatments are currently unavailable. However, the high cost of these devices can slow down adoption, especially in low-income countries. Strict approval rules for new products and a shortage of trained specialists in certain…
PR Newswire
29/09/2025

DMS GROUP : SUSTAINED GROWTH IN HALF-YEAR RESULTS FOR 2025

New half-year of business growth (+3%) in the 1st half of 2025, in a demanding international environment Strong EBITDA growth of +82% - EBITDA margin of 7.2% (vs. 4.1%) +€1.2 million improvement in net income group share Outlook: confirmation of the objective of accelerating growth in the 2nd half of 2025 in a less dynamic market context September…
Actusnews Wire
29/09/2025

Laboratory Equipment Market is expected to generate a revenue of USD 41.13…

The Laboratory Equipment Market is expanding rapidly due to rising healthcare demands, technological upgrades, and increased pharmaceutical R&D. Growing focus on automation, advanced diagnostics, and cost-effective testing is reshaping opportunities for manufacturers and suppliers worldwide. The Laboratory Equipment Market is expanding rapidly due to rising healthcare demands, technological upgrades, and increased pharmaceutical R&D. Growing focus on automation, advanced diagnostics…
PR Newswire
29/09/2025

Consortium consisting of Nordic Capital and Permira extends offer period until…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, September 29, 2025– With reference to the announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document (the "Offer Document " ) concerning the all-cash voluntary recommended public takeover offer to acquire all of the issued and…
Nasdaq GlobeNewswire
29/09/2025

Practice Management Systems Market is Projected to Reach US$36.33 billion at…

Practice Management Systems Market Set to Soar with Demand for Healthcare AutomationValued at US$ 19.65 billion in 2024. The market is projected to reach US$ 36.33 billion by 2031, registering a strong CAGR of 9.3% (2025–2031). The growth has been driven mainly due to the rising need for digital healthcare solutions, the higher number of patients, and the necessity for efficiently managing administrative processes. Practice Management Systems Market Set to Soar with Demand for Healthcare...
PR Newswire
29/09/2025

Pierre Fabre Laboratories Announces Global Partnership with Know Your Lemons…

Founded in 2014 by Corrine Ellsworth Beaumont, the Know Your Lemons Foundation focuses on breast cancer education. Inspired by personal experience and professional expertise in health communication, Corrine developed a creative approach using lemons as a visual metaphor. The 12 lemons, each representing a potential symptom of breast cancer, have become the centerpiece of the foundation's educational tools, which include an award-winning mobile app recognized at the 2025 Webby Awards for…
PR Newswire
29/09/2025
Altri  Comunicati